BTIG Reiterates 'Buy' Rating for Glaukos (NYSE: GKOS) Amid Strong Sales Growth

• BTIG reaffirmed its "Buy" rating for Glaukos, increasing its price target to $202.00.
• The company demonstrated strong sales growth, with U.S. glaucoma sales up 64% and Corneal Health revenues climbing 48%.
• Glaukos raised its 2026 revenue guidance to between $680 million and $700 million, while maintaining high 85% gross margins.

On August 20, 2026, analyst firm BTIG confirmed its "Buy" rating for Glaukos (NYSE: GKOS). Glaukos is a leading ophthalmic medical technology company that develops and sells innovative products for various eye diseases. With a market capitalization of around $11.18 billion, the company primarily focuses on advanced treatments for glaucoma and other corneal health issues.

At the time of the rating, the stock price for Glaukos was $189.55. Along with the "Buy" rating, BTIG increased its price target for the ophthalmic medical device company to $202.00. This is an increase from its previous target of $193.00, suggesting a positive outlook on the stock's future performance from the firm.

This optimism is supported by Glaukos's strong sales growth. Its U.S. glaucoma sales, led by the innovative product iDose TR, have surged by 64% to $118.50 million. Additionally, its Corneal Health revenues have climbed 48% to $30.40 million, showing significant contribution from its product Epioxa as a second key growth driver.

Reflecting this robust performance, Glaukos has raised its 2026 revenue guidance to a range between $680 million and $700 million. The company also maintains high gross margins of about 85%. Gross margin is the profit a company makes from sales after subtracting the direct costs of producing its goods.

Despite the positive outlook, Glaukos faces potential investment risks such as physician workflow challenges and potential margin pressure, as highlighted by Zacks Equity Research. This has led Zacks to maintain a "Hold" rating on the stock, offering a different perspective on its immediate prospects.